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ABSTRACT
Background Uterine clear cell and serous carcinomas
have a high propensity for locoregional and distant spread,
tend to be more advanced at presentation, and carry a
higher risk of recurrence and death than endometrioid
cancers. Limited prospective data exist to guide evidence-
based management of these rare malignancies.
Objective The American Radium Society sought to
summarize evidence-based guidelines developed by
a multidisciplinary expert panel that help to guide the
management of uterine clear cell and serous carcinomas.
Methods The American Radium Society Appropriate
Use Criteria presented in this manuscript were
developed by a multidisciplinary expert panel using
an extensive analysis of current published literature
from peer-r eviewed journals. A well-e stablished
methodology (modified Delphi) was used to rate
the appropriate use of diagnostic and therapeutic
procedures for the management of uterine clear cell
and serous carcinomas.
Results The primary treatment for non-metastatic
uterine clear cell and serous carcinomas is complete
surgical staging, with total hysterectomy, salpingo-
oophorectomy, omentectomy, and lymph node staging.
Even in early-stage disease, patients with uterine clear cell
and serous carcinomas have a worse prognosis than those
with type I endometrial cancers, warranting consideration
for adjuvant therapy regardless of the stage. Given the
aggressive nature of these malignancies, and until further
research determines the most appropriate adjuvant
therapy, it may be reasonable to counsel patients about
combined-modality treatment with systemic chemotherapy
and radiotherapy.
Conclusion Patients diagnosed with uterine clear
cell and serous carcinomas should undergo complete
surgical staging. Multimodal adjuvant therapies should
be considered in the treatment of both early-stage
and advanced-stage disease. Further prospective
studies or multi-institutional retrospective studies are
warranted to determine optimal sequencing of therapy
and appropriate management of patients based on
their unique risk factors. Long-term surveillance is
indicated due to the high risk of locoregional and
distant recurrence.

WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ Uterine clear cell and serous carcinomas have been

under-represented in large prospective trials. The
optimal treatment paradigm for each histology remains somewhat undefined.

WHAT THIS STUDY ADDS
⇒ We review current evidence supporting the staging

work-up, and surgical and adjuvant management of
early-stage and advanced-stage uterine clear cell
and serous carcinomas

HOW THIS STUDY MIGHT AFFECT RESEARCH,
PRACTICE OR POLICY
⇒ The discussion of evidence and appropriateness

rating presented here can serve as a guide to practitioners in the diagnostic and therapeutic management of uterine clear cell and serous carcinomas.

INTRODUCTION
Endometrial cancer is the most common gynecological cancer in the USA and the sixth most common
cause of cancer in women worldwide.1 Uterine clear
cell and serous carcinomas represent an aggressive
subset of endometrial cancers which tend to be more
advanced at presentation and carry a higher risk of
death than type I endometrioid cancers.2 Even in
early-stage disease, patients with uterine clear cell
and serous carcinomas have a worse prognosis than
those with type I endometrial cancers, prompting
consideration for adjuvant therapy regardless of the
stage. However, no clear consensus has been established.
Both uterine clear cell and serous carcinomas have
historically been pooled into studies with other high-
risk uterine cancers, rather than studied exclusively
in prospective clinical trials. Thus, the optimal treatment paradigm for each histology remains undefined,
especially in early-stage disease. For the purposes
of this review, early-stage disease is that confined to
the uterus/cervix (stage I/II), and late/advanced-stage
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disease is any extra-uterine or cervical spread (stage III/IV). Adjuvant
therapy options include chemotherapy, vaginal cuff brachytherapy
and pelvic±para-aortic external beam radiotherapy, or both, with
multimodality therapy typically considered for these aggressive
tumors.

METHODS
The expert panel on Radiation Oncology–Gynecology is composed
of 15 members with the multidisciplinary expertise required to
competently complete the Appropriate Use Criteria projects. The
chair is appointed by the president-elect of the American Radium
Society. Panelists are appointed for a term of 3–5 years. Panel
members responsible for this project and complete details about
the Appropriate Use Criteria committee membership procedures
are listed in the online supplemental materials 1.
An extensive and updated analysis of current medical literature
from peer-reviewed journals from January 1, 1996 to January
28, 2020 was conducted using the Preferred Reporting Items for
Systematic Reviews and Meta-
analyses3 guidelines to search
the PubMed, Embase, and Web of Science databases to retrieve
a comprehensive set of relevant articles. We developed strategies
using subject and combinations of search terms. We reviewed the
bibliographies of full articles for a comprehensive survey, and relevant studies were included. The literature was reviewed for quality
of study design, cohort size, selection bias, variability of evaluation
of participants in regard to time from exposure, and methods of
assessments. In addition, two studies published after the literature
review were added during the writing of the manuscript given their
significant relevance to the topic.
A well-established consensus methodology (modified Delphi)4
was used to rate the appropriateness of treatment procedures by
the expert panel. The expert panel was composed of a multidisciplinary panel of radiation and gynecologic oncologists as well as
a radiologist with expertise in the management of uterine cancer.

RESULTS
Rationale for Comprehensive Surgical Staging
Primary treatment for non-metastatic uterine clear cell and serous
carcinomas is complete surgical staging with total hysterectomy,
bilateral salpingo-oophorectomy, lymph node staging, omentectomy, and sampling peritoneal washings for cytology. The preferred
surgical approach has not been thoroughly investigated; while the
LAP2 trial demonstrated feasibility and safety of a laparoscopic
approach for endometrial cancers, only 12% of patients in that
study had uterine clear cell and serous carcinomas.5 In a post hoc
analysis of patients with uterine clear cell and serous carcinomas,
patterns of recurrence and survival were not affected by the surgical
approach.6 In general, when technically feasible, a minimally invasive surgical approach is preferred. Given the propensity for extra-
uterine spread, pre-operative CA-125 and CT chest/abdomen/pelvis
and/or MRI to evaluate for metastatic disease are recommended
by the Society of Gynecological Oncology.7 The role of PET/CT is
unclear as it can be difficult to distinguish 18-fluorodeoxyglucose
uptake in bowel from peritoneal implants.
1550

Often, patients present with metastatic disease, which has led to
the consideration of neoadjuvant chemotherapy prior to cytoreductive surgery. Recent data from a National Cancer Database review
suggests use of this approach accounts for nearly one-quarter of
patients who present with stage IV disease.8 Relative to propensity-
score-matched patients undergoing upfront surgery, those undergoing neoadjuvant chemotherapy had decreased mortality during
the early months following diagnosis. This benefit, however, was
lost after approximately 8 months and patients with longer survival
had better outcomes with primary surgery. Given the current
expansion in risk stratification and individualized treatment options,
more investigation is needed to understand the optimal surgical
approach for patients with de novo stage IV disease.
Rationale for Adjuvant Radiotherapy Alone
The Gynecologic Oncology Group (GOG) conducted a phase II study,
GOG 94, evaluating the role of whole abdominal radiotherapy in
stage I/II uterine clear cell and serous carcinomas.9 Following
debulking to <2 cm residual disease (omentectomy not required), 34
patients received whole abdominal radiotherapy to 30 Gy at 1.5 Gy
per fraction, with a pelvic boost of 19.8 Gy at 1.8 Gy per fraction.
Patients with uterine clear cell carcinoma (13 patients) had a higher
5-year progression-free survival than those with uterine serous
carcinoma (21 patients), 54% vs 38%, respectively. Still, over half
of all recurrences were in the radiotherapy field, suggesting that
whole abdominal radiotherapy alone was not adequate.9 In addition, there was a 17% rate of grade 3–4 gastrointestinal toxicity,
much higher than is observed in modern series using conformal
techniques. While this study used outdated radiation techniques,
the results suggest that uterine clear cell carcinomas might have
better outcomes than uterine serous carcinomas. The results also
raised concern that chemotherapy should be considered in combination with radiotherapy for patients with both histologies.
In the pooled analysis of high-risk endometrial cancers treated
on the randomized NSGO-EC-9501/EORTC-55991 and MaNGO-
ILIADE-
III trials, where radiotherapy alone was compared with
radiotherapy combined with chemotherapy, the addition of chemotherapy to radiotherapy resulted in an overall 36% reduction in risk
of relapse or death when all histologies were combined. However,
among the 140 patients with uterine clear cell and serous carcinomas, the benefit of chemotherapy was not demonstrated.10
Comparably, a National Cancer Database review of uterine serous
carcinomas suggested a survival benefit from vaginal brachytherapy
in stage IA/II disease, while only stage IB/II disease demonstrated
a survival benefit from chemotherapy.11 A second National Cancer
Database review also observed a survival benefit from adjuvant
vaginal brachytherapy for both invasive and non-invasive stage IA
uterine clear cell and serous carcinomas.12 For non-myoinvasive
stage IA tumors, the benefit of adjuvant therapy is less clear and
may be limited to those patients who have not undergone a staging
lymphadenectomy.13
Lastly, the phase III GOG 0249 trial included a subset of patients
with stage I/II uterine clear cell and serous carcinomas (88
with uterine serous and 28 with uterine clear cell carcinomas).
Patients were randomized to pelvic radiotherapy (45–50.4 Gy),
or vaginal brachytherapy plus three cycles of paclitaxel and
carboplatin. At 53 months' median follow-up, combined vaginal
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brachytherapy-chemotherapy was not superior to pelvic radiotherapy and was associated with more frequent and severe acute
toxicity.14
Rationale for Adjuvant Chemotherapy Alone
Since the publication of GOG 122, which included 17 patients
with uterine clear cell carcinomas and 83 with uterine serous
carcinomas, and showed that chemotherapy resulted in improved
overall survival compared with whole abdominal radiotherapy
(52% vs 42%) in treating locally advanced disease of all histologic
subtypes, chemotherapy has become part of the standard treatment for locally advanced disease.15 However, chemotherapy was
also associated with increased grade 3–4 toxicities and resulted in
nearly 20% risk of locoregional recurrence. Moreover, the overall
poor survival outcomes with each mono-modal approach highlight the need for improved treatment strategies. While the radiotherapy techniques used in this study are outdated, the observed
improved survival nevertheless provided support for chemotherapy
as standard treatment for locally advanced endometrial cancers of
all histologic subtypes.
A more recent prospective study, GOG 0258, included a subset
of patients with stage I–II uterine clear cell and serous carcinomas
with positive peritoneal cytology; 131 patients with uterine serous
carcinomas and 22 with uterine clear cell carcinomas. Patients
were randomized between chemoradiotherapy and chemotherapy
alone (carboplatin plus paclitaxel) for six cycles. The combined
chemoradiotherapy arm consisted of pelvic radiotherapy to 45 Gy
with concurrent cisplatin followed by four cycles of carboplatin
and paclitaxel. At 60 months, chemoradiotherapy was associated
with a lower incidence of vaginal recurrence (2% vs 7%; HR=0.36)
and pelvic and para-aortic lymph node recurrence (11% vs 20%;
HR=0.43) than chemotherapy alone. Nevertheless, distant recurrence appeared more common in the chemoradiotherapy arm (27%
vs 21%; HR=1.36), and there was no difference in disease-free
survival or grade 3–5 toxicity between the two study groups.16
Rationale for Combined-Modality Therapy (Chemotherapy and
Radiation Treatment)
In light of the high risk of relapse with single-modality therapy for
both uterine clear cell and serous carcinomas, a combined-modality
approach is often considered in an effort to prevent both local and
distant recurrences. For early-stage disease, several retrospective
series have evaluated the role of vaginal brachytherapy in combination with chemotherapy. In one multi-institutional analysis of 414
patients with stage IA uterine clear cell and serous carcinomas,
vaginal brachytherapy and chemotherapy were both associated
with improved local control and disease-free survival on multivariable analysis.17
For advanced-stage disease, the value of radiotherapy added to
chemotherapy for uterine clear cell and serous carcinomas remains
controversial. A prospective phase II study of patients with stage I–
IIIA uterine serous carcinomas who underwent adjuvant concurrent
weekly paclitaxel (50 mg/m2) and pelvic radiotherapy to 45 Gy plus
vaginal brachytherapy followed by four cycles of adjuvant paclitaxel
(135 mg/m2) resulted in a 5- year overall survival, progression-free
survival, and local control rate for all patients of 85%, 83%, and
87%, respectively.18 This study lends support to consideration of
adjuvant concurrent paclitaxel and pelvic radiotherapy followed by

four courses of systemic paclitaxel for surgically staged I–III uterine
serous carcinomas.
The recently published PORTEC-3 trial investigated the benefit
of combined-modality therapy compared with pelvic radiotherapy
alone in patients with high-risk endometrial cancer, 105 of whom
had uterine serous carcinoma and 62 had uterine clear cell
carcinoma, stage I–III. Patients were randomized to pelvic radiotherapy alone (48.6 Gy) or radiotherapy with concurrent cisplatin
(two cycles) and adjuvant carboplatin/paclitaxel (four cycles).19 In
the updated analysis, both overall and failure-free survival were
significantly improved in patients who received combined-modality
therapy, with the greatest benefit in patients with stage III or uterine
serous carcinoma, or both. Patients with uterine serous carcinoma
were found to have a lower failure-free survival and overall survival
than those with other histologies, and for these patients there was a
significant improvement in overall survival (absolute improvement
19%) and failure-free survival (absolute improvement 12%) with
chemoradiotherapy compared with radiotherapy alone.20
While the optimal scheduling of chemotherapy and radiotherapy
is not established, a phase II study investigated outcomes associated with pelvic radiotherapy ‘sandwiched’ between six cycles
of carboplatin/paclitaxel in uterine serous carcinoma (three cycles
prior to radiotherapy and three cycles following radiotherapy).21 For
stage I/II disease, the 2- and 5 year overall survival was 96% and
81%, respectively. For stage III/IV disease, the 2- and 5 year overall
survival was 64% and 18%, respectively.22 A separate prospective phase II study examined stage I–IVA uterine serous carcinoma
treated with sequential adjuvant paclitaxel (175 mg/m2) and carboplatin (area under curve 6) for four cycles, followed by pelvic radiotherapy (50.4 Gy). Thirteen of 29 patients with stage I–III disease
(44.8%) had a recurrence at 28 months, suggesting that further
study is needed to determine the optimal sequencing strategy.23
Rationale for Targeting Human Epidermal Growth Factor
Receptor 2 (HER2)
Overexpression/amplification of the oncogene human epidermal
growth factor receptor 2 (HER2) has been identified in uterine
clear cell and serous carcinomas to varying degrees,24–26 and clinical trials are now incorporating anti-HER2 directed therapy into
experimental paradigms. A phase II trial evaluated 61 patients with
advanced/recurrent uterine serous carcinomas overexpressing
HER2 and randomized patients to carboplatin/paclitaxel±trastuzumab. Patients who received trastuzumab had equal toxicity
with an improved progression-free survival of 12.6 vs 8.0 months
(p=0.005). On subcohort analysis, the greater benefit was seen in
patients treated upfront with trastuzumab, compared with those
with recurrent disease. In the setting of HER2-expressing locally
advanced or recurrent uterine serous carcinoma, emerging data
appear to support the consideration of adding trastuzumab to platinum and taxane-based chemotherapy.27
Patient-focused Planning Techniques
For patients treated with vaginal brachytherapy, the target volume
should include the proximal 3–4 cm of the vaginal canal. Various
dose prescriptions could be used, and we endorse those specified
by the American Brachytherapy Society guidelines.28 In addition,
given the low morbidity and excellent local control reported with
shorter fractionation schemes, a 3, 4, or 5 fraction approach are
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preferred compared with longer fractionation regimens. When
treating with external beam radiotherapy, a CT-based 3D conformal
or intensity-modulated radiotherapy technique should be used. The
randomized phase III trial GOG 1203 comparing intensity-modulated
radiotherapy with a four-field approach found an improvement in
patient-reported gastrointestinal and genitourinary symptoms with
intensity-modulated radiotherapy.29 Similarly, there is probably
little to no role for whole abdominal radiotherapy for patients with
uterine clear cell and serous carcinomas, as this approach carries a
known increased risk in treatment-related toxicity without a known
clinical benefit.
When using intensity-
modulated radiotherapy, careful delineation of the nodal and vaginal clinical target volumes is necessary. Creating a vaginal internal target volume is recommended to
account for inter-fraction motion due to bladder filling and rectal
distention. The panel endorses the NRG Oncology international
collaborative atlas of contouring guidelines in the post-operative
setting.30 The recommended clinical target volume dose is
45–50.4 Gy at 1.8–2.0 Gy per fraction, and an appropriate planning
tumor volume margin is typically 5–7 mm, depending on the immobilization technique and image guidance available.30
Surveillance
The panel supports a complete history and abdominopelvic-
rectal examination conducted every 3 months for the first 2 years
and semiannually thereafter as suggested by the Society of

Gynecological Oncology.31 It is recommended that all symptomatic
patients undergo a targeted investigation to rule out recurrence,
which often includes CT chest/abdomen/pelvis, MRI and/or PET/CT,
depending on the clinical scenario.
Consensus and Recommendations from Expert Panel
The panel strongly recommends vaginal brachytherapy alone
or systemic therapy+vaginal radiotherapy as adjuvant treatment for a non-invasive surgically staged International Federation of Gynecology and Obstetrics (FIGO) stage IA uterine clear
cell and serous carcinomas.
► For patients who had a hysterectomy without lymph node
dissection, a pelvic and para-aortic lymph node dissection may
be appropriate, depending on the patient’s unique risk factors
and goals of therapy.
► Adjuvant chemotherapy and radiation therapy is usually appropriate for a typical case of FIGO stage IB uterine clear cell and
serous carcinomas; an exception is the option for pelvic radiotherapy alone for a surgically staged IB uterine clear cell carcinoma with minimal risk features.
► Carboplatin and paclitaxel is usually appropriate for patients
treated with adjuvant chemotherapy. Consideration may be
made for concurrent cisplatin during external beam radiotherapy, but there was disagreement among the panel about
the appropriate schedule (weekly vs every 3 weeks) for concurrent cisplatin.
►

Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram: searches run on
January 28, 2020.
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Tumor volume-directed radiation treatment is usually appropriate in the adjuvant setting of patients with advanced-stage
uterine clear cell and serous carcinomas. There are insufficient data to support the routine use of one radiation technique over the other (vaginal brachytherapy vs external beam
radiotherapy) when used in combination with chemotherapy.
Intensity-modulated radiotherapy is the recommended technique when external beam radiotherapy is recommended.
For patients who undergo pelvic and para-aortic lymph node
dissection and are pN0, the panel recommends omitting the
para-aortic nodes from the external beam field. There was
disagreement on whether to target para-aortic lymph nodes
when the pelvic lymph nodes are known to be involved yet the
para-aortic sampling was negative.
► For patients receiving vaginal brachytherapy, targeting the
entire vaginal length was not recommended by panel members.
In addition, the panel endorses the American Brachytherapy
Society guidelines, preferring 3, 4, or 5 fraction regimens
compared with longer fractionation regimens.
► Routine use of adjuvant whole abdominal radiotherapy is not
recommended outside of a clinical trial setting.
► For patients with residual nodal disease after surgery, the panel
recommends treatment with definitive intent when feasible.
When boosting gross residual nodal disease, the panel thought
a simultaneous integrated boost and sequential boost were
both reasonable options.
► In the setting of locally advanced uterine serous carcinoma, the
panel recommends ordering HER2 testing and consideration for
HER2-directed therapy if a tumor is known to be HER2-positive.
► Routine surveillance after treatment with routine imaging in the
first 3 years is recommended. There was disagreement among
the panel about whether this should be done every 3, 6, or 12
months.
The American Radium Society Appropriate Use Criteria and its
expert panels have developed criteria for determining appropriate
radiologic procedures for diagnosis and treatment of specified
medical condition(s). These criteria are intended to guide radiologists, radiation oncologists, and referring physicians in making
decisions about radiologic imaging and treatment. Generally, the
complexity and severity of a patient’s clinical condition should
dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the
patient’s condition are ranked. Other imaging studies necessary to
evaluate other co-existent diseases or other medical consequences
of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of
appropriate imaging procedures or treatments. Imaging techniques
classified as investigational by the US Food and Drug Administration
have not been considered in developing these criteria; however,
study of new equipment and applications should be encouraged.
The ultimate decision about the appropriateness of any specific
radiologic examination or treatment must be made by the referring
physician and radiologist in light of all the circumstances presented
in an individual examination.
►
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